Table Of Content

international journal of — pharmaceutics ; 4EV IuE}4 R . International Journal of Pharmaceutics 148 (1996) 241—242 Author index Alderborn, G., see Eriksson, M. 148, 149 Duncan, R., see Carrefio-Gomez, B. 148, 231 Alvarez-Fuentes, J., I. Caraballo, A. Boza, J.M. Llera, M.A. Duncan, R., see Gianasi, E. 148, 139 Holgado, M. Fernandez-Arévalo, Study of a complexation process between naltrexone and Eudragit® L as an oral Eriksson, M., G. Alderborn, C. Nystrém, F. Podezeck, J.M. controlled release system 148, 219 Newton, Comparison between and evaluation of some Arias-Blanco, M.J., see Moyano, J.R. 148, 211 methods for the assessment of the sphericity of pellets 148, 149 Baie, S., see Mahrag Tur, K. 148, 63 Bernkop-Schniirch, A., see Valenta, C. 148, 131 Fang, J.-Y., see Wu, P.-C. 148, 41 Boza, A., see Alvarez-Fuentes, J. 148, 219 Farinha, A., see Lewis, D. 148, 177 Breton, P., see Roy, D. 148, 165 Faustino, E., see Lewis, D. 148, 177 Brojo, A.P., see Pina, M.E. 148, 73 Fernandes de Aguiar, P., see Inghelbrecht, S. 148, 103 Bru, N., see Roy, D. 148, 165 Fernandez-Arévalo, M., see Alvarez-Fuentes, J. 148, 219 Burnouf, T., see Flament, M.P. 148, 93 Flament, M.P., P. Leterme, T. Burnouf, A.T. Gayot, Jet nebulisation: influence of dynamic conditions and nebuliser Caputo, O., see Cavalli, R. 148, 47 on nebulisation quality. Application to the «1 protease Caraballo, I., see Alvarez-Fuentes, J. 148, 219 inhibitor 148, 93 Carlotti, M.E., see Cavalli, R. 148, 47 Florence, A.T., see Gianasi, E. 148, 139 Carreno-Gomez, B., R. Duncan, Evaluation of the biological properties of soluble chitosan and chitosan micro- Gasco, M.R., see Cavalli, R. 148, 47 spheres 148, 231 Gayot, A.T., see Flament, M.P. 148, 93 Cavalli, R., O. Caputo, M.E. Carlotti, M. Trotta, C. Scarnec- Gianasi, E., F. Cociancich, I.F. Uchegbu, A.T. Florence, R. chia, M.R. Gasco, Sterilization and freeze-drying of drug- Duncan, Pharmaceutical and biological characterisation of a free and drug-loaded solid lipid nanoparticles 148, 47 doxorubicin-polymer conjugate (PK 1) entrapped in sorbitan Ch’ng, H.-S., see Mahrag Tur, K. 148, 63 monostearate Span 60 niosomes 148, 139 Cociancich, F., see Gianasi, E. 148, 139 Ginés, J.M., see Moyano, J.R. 148, 211 Couvreur, P., see Roy, D. 148, 165 Giordano, F., see Moyano, J.R. 148, 211 Guillon, X., see Roy, D. 148, 165 Dalla Fini, G., see Realdon, N. 148, 155 Dal Zotto, M., see Realdon, N. 148, 155 Hancock, B.C., P. York, R.C. Rowe, The use of solubility Deasy, P.B., M.F.L. Law, Use of extrusion-spheronization to parameters in pharmaceutical dosage form design 148, | develop an improved oral dosage form of in- Hirakawa, Y., see Narisawa, S. 148, 85 domethacin 148, 201 Holgado, M.A., see Alvarez-Fuentes, J. 148, 219 De Backer, P., see Inghelbrecht, S. 148, 103 Huang, Y.-B., see Wu, P.-C. 148, 41 De Baets, P., see Inghelbrecht, S. 148, 103 Devarajan, P.V., see Mandlekar, S.V. 148, 117 Inghelbrecht, S., J.-P. Remon, P. Fernandes de Aguiar, B. Dickinson, P.A., 1.W. Kellaway, G. Taylor, D. Mohr, K. Walczak, D.L. Massart, F. Van De Velde, P. De Baets, H. Nagels, H.-M. Wolff, In vitro and in vivo release of estra- Vermeersch, P. De Backer, Instrumentation of a roll com- diol from an intra-muscular microsphere formulation 148, pactor and the evaluation of the parameter settings by 55 neural networks 148, 103 242 Author index Kellaway, I.W., see Dickinson, P.A. 148, 55 Ragazzi, E., see Realdon, N. 148, 155 Keré, J., see Senéar-Bozit, P. 148, 123 Realdon, N., E. Ragazzi, M. Dal Zotto, G. Dalla Fini, Lay- Kinget, R., see Ugwoke, M.I. 148, 23 ered excipient suppositories: the possibility of modulating Knez, Z., see Sentéar-Bozi¢é, P. 148, 123 drug availability 148, 155 Kobayashi, M., see Narisawa, S. 148, 85 Remon, J.-P., see Inghelbrecht, S. 148, 103 Rowe, R.C., see Hancock, B.C. 148, | Law, M.F.L., see Deasy, P.B. 148, 201 Roy, D., X. Guillon, F. Lescure, P. Couvreur, N. Bru, P. Lescure, F., see Roy, D. 148, 165 Breton, On shelf stability of freeze-dried poly(methylidene Leterme, P., see Flament, M.P. 148, 93 malonate 2.1.2) nanoparticles 148, 165 Lewis, D., M. Paulo, E. Faustino, A. Farinha, In vitro com- parative studies of transdermal nicotine delivery sys- Scarnecchia, C., see Cavalli, R. 148, 47 tems 148, 177 Schwartz, M., see Valenta, C. 148, 131 Llera, J.M., see Alvarez-Fuentes, J. 148, 219 Senéar-Bozié, P., S. Sréit, Z. Knez, J. Keré, Improvement of nifedipine dissolution characteristics using supercritical Mahrag Tur, K., H.-S. Ch’ng, S. Baie, Use of bioadhesive CO, 148, 123 polymer to improve the bioavailability of griseofulvin 148, Sher, A., M. Veber, M. Marolt-Gomiséek, Spectroscopic and 63 Mandlekar, S.V., S.S. Marathe, P.V. Devarajan, A novel polarographic investigations: copper(II)-penicillin deriva- tives. 148, 191 raft-forming antacid suspension using a natural dietary Sousa, A.T., see Pina, M.E. 148, 73 fibre 148, 117 Marathe, S.S., see Mandlekar, S.V. 148, 117 Sréic, S., see Senéar-Bozi¢, P. 148, 123 Marolt-Gomistéek, M., see Sher, A. 148, 191 Massart, D.L., see Inghelbrecht, S. 148, 103 Taylor, G., see Dickinson, P.A. 148, 55 Mohr, D., see Dickinson, P.A. 148, 55 Trotta, M., see Cavalli, R. 148, 47 Moyano, J.R., M.J. Arias-Blanco, J.M. Ginés, F. Giordano, Tsai, Y.-H., see Wu, P.-C. 148, 41 Solid-state characterization and dissolution characteristics of gliclazide-f-cyclodextrin inclusion complexes 148, 211 Uchegbu, I.F., see Gianasi, E. 148, 139 Mufioz-Ruiz, A., P. Paronen, Particle and powder properties Ugwoke, M.I., N. Verbeke, R. Kinget, Microencapsulation of of cyclodextrins 148, 33 apomorphine HCl with gelatin 148, 23 Nagata, M., see Narisawa, S. 148, 85 Valenta, C., A. Bernkop-Schniirch, M. Schwartz, Modification Nagels, K., see Dickinson, P.A. 148, 55 of lysozyme with cinnamaldehyde: a strategy for construct- Narisawa, S., M. Nagata, Y. Hirakawa, M. Kobayashi, H. ing novel preservatives for dermatics 148, 131 Yoshino, An organic acid-induced sigmoidal release system Van De Velde, F., see Inghelbrecht, S. 148, 103 for oral controlled-release preparations. III. Elucidation of Veber, M., see Sher, A. 148, 191 the anomalous drug release behavior through osmotic Verbeke, N., see Ugwoke, M.I. 148, 23 pumping mechanism 148, 85 Vermeersch, H., see Inghelbrecht, S. 148, 103 Newton, J.M., see Eriksson, M. 148, 149 Nystrém, C., see Eriksson, M. 148, 149 Walczak, B., see Inghelbrecht, S. 148, 103 Wolff, H.-M., see Dickinson, P.A. 148, 55 Paronen, P., see Mufoz-Ruiz, A. 148, 33 Wu, P.-C., Y.-B. Huang, J.-Y. Fang, Y.-H. Tsai, In vitro Paulo, M., see Lewis, D. 148, 177 Pina, M.E., A.T. Sousa, A.P. Brojo, Enteric coating of hard percutaneouus absorption of captopril 148, 41 gelatin capsules. Part 2—Lioavailability of formaldehyde treated capsules 148, 73 York, P., see Hancock, B.C. 148, | Podezeck, F., see Eriksson, M. 148, 149 Yoshino, H., see Narisawa, S. 148, 85